Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter ...

The Company is in AdvancedStagesof Commercial U.S. Partnership Discussions for D-PLEX₁₀₀Positive FDA Pre-NDA Feedback Supports Rolling NDA ...

Q4 2025 Management View CEO Dikla Akselbrad described 2025 as “a pivotal year for PolyPid,” highlighting the completion of ...

Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript February 10, 2026 Exelixis, Inc. beats earnings expectations. Reported EPS is $0.94, expectations were $0.77. Operator: Good day, ladies ...

As we continue to invest in modernizing our electric and gas infrastructure, remain focused on supporting economic growth, ...

Spero Therapeutics’ oral antibiotic tebipenem shows Phase 3 success and supports GSK’s NDA resubmission. Click here to read ...

Consistent performance across NDA 155 and 156 reinforces the standing of Doon Defence Dreamers in India’s defence education ecosystem. Doon Defence Dreamers has reinforced its reputation in India’s de ...

KalVista Pharmaceuticals, Inc. is rated a Strong Buy due to EKTERLY's global launch and robust initial sales momentum. Read ...

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for ...

The 'jungle raj' spectre proved potent in the NDA sweep of Bihar. In the Bangladesh national election, the Jamaat-e-Islami is using a similar playbook against the BNP ...